Biomarkers in Vascular Ehlers-Danlos Syndrome (MEDIC) | oneedsvoice

welcome to oneEDSvoice

- a positively charged Ehlers Danlos Syndrome community.
  • join today!
rareClinical
completed

Biomarkers in Vascular Ehlers-Danlos Syndrome (MEDIC)

study id #: NCT02165085

condition: Vascular Ehlers-Danlos Syndrome

status: completed

purpose:

The purpose of this study is to determine whether patients with vascular Ehlers-Danlos syndrome present significant and specific changes of arterial endothelial and smooth muscular cell signalling/secretion, in comparison to matched healthy volunteers and patients with spontaneous arterial dissections.

start date: June 2013

estimated completion: July 2015

last updated: March 17, 2016

phase of development: N/A

size / enrollment: 211

study design: Observational Model: Case Control
Time Perspective: Prospective

study description: Vascular Ehlers-Danlos syndrome is a rare inherited disease which confers exceptional organ fragility in seamingly healthy young adults. The disease is caused by a mutation in the COL3A1 gene encoding type III collagen, critical to ensure physical resistance to mechanical stress of hollow organs. The disease results in increased tissular fragility, responsible of spontaneous arterial ruptures and dissections and spontaneous bowel perforations. The life-expectancy of patients with vascular Ehlers-Danlos syndrome is reduced by these recurring accidents. The exact mechanisms that trigger arterial accidents are unknown. Recent findings suggest a possible deleterious effect of inflammation and a possible dysregulation of the TGF-beta pathway. Thus, the purpose of this study is to identify further alterations in vascular endothelial and smooth muscular cell signalling/secretion, and to confirm previously suggested mechanisms of arterial accidents in vEDS patients.

primary outcomes:

  • Diagnostic value of plasma biomarkers SEDv [ Time Frame: At the end of study (2 years after period of inclusion for first patient) ]
    Analysis of the diagnostic value of different levels of plasma concentrations of microRNAs

secondary outcomes:

  • Reference value of biomarkers [ Time Frame: At the end of study (2 years after period of inclusion for first patient) ]
    Compare patients with controls SEDv and two populations (patients with arterial accident spontaneous and healthy volunteers):microRNAs, the expression of circulating markers of tissue remodeling (plasma procollagen type I and III), the expression of a marker of inflammation (sensitivity C-reactive protein CRPus)

inclusion criteria: - Patients with vascular Ehlers-Danlos syndrome must have been positively tested for a pathogenic mutation within the COL3A1 gene.
- In patients with arterial dissection(s) any associated systemic arterial disease must have been ruled out, especially vascular Ehers-Danlos syndrome

exclusion criteria: -All subjects must not present any chronic systemic disease, any acute disease within seven days prior to enrollment, diabetes mellitus and arterial hypertension.

sponsor: Assistance Publique - Hôpitaux de Paris

investigators: Michael Frank, MD Centre de Reference des Maladies Vasculaires Rares, Hopital Europeen Georges Pompidou

locations: France

expertly curated content related to this topic